Bionano Genomics, Inc.
NASDAQBionano Genomics heads into today's earnings report carrying meaningful short pressure — and a lending market that reinforces the bearish lean. Short sellers hold nearly 11% of the free float, a substantial position for a micro-cap genomics company trading at $1.25. That figure has been drifting lower over the past month, falling roughly 5%, but the retreat has been gradual rather…
Snapshot as of 22 Jun 2026
Bionano Genomics heads into today's earnings report carrying meaningful short pressure — and a lending market that reinforces the bearish lean. Short sellers hold nearly 11% of the free float, a substantial position…
Bionano Genomics heads into the post-earnings session with a story that is harder to dismiss than its micro-cap price suggests — but short sellers have yet to be convinced. The company reported Q1 2026 earnings after…
Bionano Genomics enters its May 13 earnings call with a management vacuum at the top — and shorts have been watching closely all week. The headline from Wednesday evening tells the story: chairman Al Luderer was named…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BNGO — free to start on ORTEX.
Sign up for free →Open BNGO on ORTEX